PCM
IGC icon

Penserra Capital Management’s IGC Pharma IGC Stock Holding History

Penserra Capital Management’s Portfolio IGC Stock Details IGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-56,068
Closed -$98K – 1489
2021
Q2 		$98K Buy
+56,068
New +$85.6K ﹤0.01% 797

Other funds holding IGC

IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Penserra Capital Management's IGC Position: Q3 2021 in Review

Penserra Capital Management sold out of IGC Pharma (IGC) in Q3 2021, closing a stake of 56,068 shares — an estimated $98K sold.

Penserra Capital Management first reported a position in IGC in Q2 2021 and held it in 1 quarter. The position peaked at $98K in Q2 2021. 32 funds tracked by Wall St. Rank hold IGC as of Q3 2021.

  • Penserra Capital Management reported no remaining IGC Pharma position as of Q3 2021 after selling out during the quarter.
  • Penserra Capital Management sold 56,068 IGC Pharma shares in Q3 2021, an estimated $98K.
  • Penserra Capital Management first reported a position in IGC Pharma in Q2 2021 and held it in 1 quarter.
  • Penserra Capital Management's IGC Pharma position peaked at $98K in Q2 2021.
  • 32 funds tracked by Wall St. Rank held IGC Pharma as of Q3 2021.

Based on Penserra Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.